Biopharma

Top 10 oncology breakthroughs shared at ASCO 2021

Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In the following article, we share our analysis of these exciting breakthroughs, data and takeaways for life sciences executives.   “Equity: Every Patient. Everyday. Everywhere” The ASCO Annual Meeting is the […]

Amazon and Walmart wade into U.S. telehealth and digital pharmacy

The e–commerce giants’ evolving healthcare offerings could put pressure on drug makers, as well as PBMs and telehealth vendors Amazon’s healthcare ambitions have long been the subject of intense speculation – and not a little anxiety – for players throughout the sector. Amazon’s massive scale and world-beating digital capabilities give it the power to disrupt nearly any business it enters. So you could almost hear healthcare company CEOs taking a sharp breath and sitting up a little straighter when, in March, Amazon announced that it would offer its in-house health […]

State review boards take on drug prices amid Congressional inaction

How are states tackling high drug prices and increasing affordability? Clarivate market access expert Stephanie Hoops discusses the emergence of affordability review boards. Done waiting for Congress to take action on drug prices, states are increasingly enacting laws that create drug affordability review boards. As is done with utilities or insurance premiums, the boards allow states […]

Immuno-oncology breakthroughs: from precision medicine to modulating the tumor microenvironment

The European Association for Cancer Research (EACR) explores the most exciting cancer research from Europe and globally. Clarivate Life Sciences Editor Joan Tur reviews the top three trends from their recent immuno-oncology event, and their implications for the future of cancer treatment. Despite pandemic-driven clinical trial delays across multiple therapy areas, novel immuno-oncology approaches continue […]

DRG becomes Clarivate

One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in this journey as the DRG brand now becomes one with the Clarivate brand. Starting today, you will begin to see the DRG brand less and less as we migrate communications and, look and […]

Digital pharmacies posed for growth in a post-pandemic world

Digital pharmacies, which provide a faster and easier way to get prescriptions, are implementing new technologies to improve prescription fulfillment and delivery. Digital pharmacies have the potential to help reduce medication errors, increase access to prescriptions and provide pharmacists more time to counsel patients. These factors can boost adherence among patients. Market dynamics, such as […]

The unmet need for precision medicine in Lyme disease

Lyme disease cases and complications are rising, yet current treatment regimens are proving to be insufficient. Clarivate Senior Science Editor Shyama Ghosh and Managing Editor Stephen DuPraw collaborated with Principal Epidemiologist Swarali Tadwalkar to review the current and emerging treatment landscape and what’s needed to better serve patients.   In the U.S., about 30 million […]

How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.

In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them, employer-sponsored health coverage. This drove a spike in the rate of uninsured patients, along with a shift from commercial employer-sponsored plans to other coverage options, such as coverage bought through state- and federal government-run health insurance exchanges, Medicaid and short-term health insurance plans.   Implemented as part of the 2010 Affordable Care Act reforms, health insurance exchanges vary from state […]